Assessing acute nicotine impact on choroidal thickness: a randomized, double-blinded study comparing smoking cessation aids, including nicotine gum and electronic cigarettes.

What Was Tested

Researchers studied Therapeutic nicotine (patch, non-peptide) in this randomized controlled trial publication.

Who Took Part

The study group was 20 participants.

The age groups tagged for this paper are young adults and adults, both men and women.

In a randomized double-blinded prospective cross-sectional study, 20 healthy participants (mean age ± standard deviation: 23 ± 2.36 years) were randomly assigned to either the nicotine gum or vaping group.

How the Study Was Run

The design is described as randomized and double-blind.

Because people in this Therapeutic nicotine (patch, non-peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Therapeutic nicotine (patch, non-peptide) study, the assignments were hidden from both participants and investigators until the end.

What Was Measured

Topics PubMed links to this paper include Choroid, Tomography, Optical Coherence, Cross-Sectional Studies, Nicotine, Electronic Nicotine Delivery Systems, Smoking Cessation and Tobacco Use Cessation Devices.

Author keywords: Choroidal thickness, Electronic cigarette vape, Nicotine consumption and Nicotine gum.

What This Means in Plain Language

The paper is a randomized and double-blind study of Therapeutic nicotine (patch, non-peptide) in 20 participants.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2024 (International ophthalmology), a journal based in Netherlands.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.